DIRECTING THE IMMUNE RESPONSE THROUGH DESIGNED NANOMATERIALS

THE IMMUNE SYSTEM, AND ESPECIALLY THE INNATE ONE, MAY BE AN INFLEXIBLE ENEMY OF NANOMEDICINE. HOWEVER, IF WE KNOW HOW OUR ENEMY THINKS, WE CAN DIRECT ITS ACTION AND EVEN USE ITS POWER TO OUR ADVANTAGE.

what is Dirnano

DIRNANO comprises several European researchers, professionals, entrepreneurs, edutainers and business trainers

  • Scientists have complementary expertise;
  • Integrated team will ensure design of nanoparticles core or coating and derivatization;
  • R&D companies will contribute to searching for new innovative coating agents, chance to develop optimal stealth or immune-targeted nanoparticles and develop new immunological tools;
  • Partner Organizations will support workshops and classes.

PURPOSE OF THE PROJECT

Dirnano provides a highly integrated and interdisciplinary training of next-generation Early Stage Researchers (ESRs) at the interface of nanopharmaceutical bioengineering and its translation on preclinical and human immunology.

Dirnano will develop biocompatible nanopharmaceuticals with either “super”-stealth or immune- specific behavior for cancer immunotherapy and vaccination by mapping nanoparticle-immune interactions through two core approaches:

  1. inception of novel surface engineering approaches, based on new organic polymers, zwitterionic lipids and conjugation chemistry strategies,
  2. engineering of host or microbial-derived modulators of innate immunity (e.g. complement system).

applications

DISCOVER ALL APPLICATIONS
Officially starts
01/10/2021
Period
4 YEARS
€ Budget more than
4 MILLIONS
European partners
12
Participating organisations
5
Early Stage Researchers (ESRs) in the fields of nanomedicine
12
SUBSCRIBE TO OUR NEWSLETTER
Consent*
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956544
© 2022 University of Padova - All rights reserved P.Iva 00742430283
chevron-right-circle